Lyme Disease Epidemiology & Surveillance in Virginia David Trump, MD, MPH, MPA State Epidemiologist Director, Office of Epidemiology Virginia Department.

Slides:



Advertisements
Similar presentations
Outbreak investigation report Agnes Hajdu EpiTrain III, Jurmala, Latvia Based on EPIET material.
Advertisements

Nick Curry, MD, MPH Infectious Diseases Prevention Section
Lyme Disease Tracking & Prevention Virginia Department of Health
Tick-borne Disease Surveillance Catherine M. Brown, DVM, MSc, MPH State Public Health Veterinarian Massachusetts Department of Public Health.
Opioid-Related Deaths and Mortality Rates by County, Wisconsin Residents Office of Health Informatics and AIDS/HIV and Hepatitis C Program Bureau.
Partnering for Healthcare- Associated Infection Prevention Andrea Alvarez, MPH HAI Program Coordinator Office of Epidemiology Virginia Department of Health.
Asthma in Minnesota Slide Set Asthma Program Minnesota Department of Health January 2013.
HIV Epidemiology Program: Epidemiology of HIV and AIDS in Los Angeles County Presentation to Public Health Commission October 28, 2010 Douglas M. Frye,
7/16/08 1 New Mexico’s Indicator-based Information System for Public Health Data (NM-IBIS) Community Health Assessment Training July 16, 2008.
1 Valley Fever Edward Moreno, MD, MPH Director and Health Officer Fresno County Department of Public Health David Luchini, PHN Division Manager of Community.
Diagnosis and Management of Acute HIV Infection HIV Clinical Guidelines from the New York State Department of Health AIDS Institute January 2010 HIV CLINICAL.
Hepatitis A to E: An Overview
Ebola Facts October 28, /28/14 Identify, Isolate, Inform: ED Evaluation and Management The following diagram provides guidance on evaluation and.
HIV and Aging Kathleen K Casey, MD Director, AIDS Ambulatory Care Center Jersey Shore University Medical Center.
Lyme Prevention/Control at the Local Level David Goodfriend, MD, MPH Health Director, Loudoun Health District
County Health Authority Theoffice of The office of Phase II:
Plague CDC, AFIP. Diseases of Bioterrorist Potential Learning Objectives Describe the epidemiology, mode of transmission, and presenting symptoms of disease.
Northwest Center for Public Health Practice University of Washington School of Public Health and Community Medicine 1 Preparing for and Responding to Bioterrorism:
Estimating the number of Kentuckians living with HIV disease with unmet needs for HIV-related primary care in calendar year 2010  Reducing new HIV infections.
Bioterrorist Agents: Tularemia
Evaluation of Human Lyme Disease Surveillance in Maine, 2008 – 2010 Megan Saunders 1,2 MSPH, Sara Robinson 2 MPH, Anne Sites 2 MPH MCHES 1 University of.
HIV INCIDENCE SURVEILLANCE (HIS) PROGRAM California Department of Public Health Office of AIDS Surveillance Section.
An Introduction to HIV Incidence Surveillance (HIS) in California California Department of Public Health Office of AIDS.
Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.
Screening of Human and Animal Sera from Egypt and Hong Kong Perera et al. Euro Surveill. 2013;18(36):pii=20574 Sampled 1343 Human, 625 animals.
Epidemiology of HIV-2 infection in the U.S, Lata Kumar MS, MPH Richard Selik MD Division of HIV/AIDS Prevention National Center for HIV/AIDS,
Testing algorithms used at Bureau of Labs Michigan Department of Community Health Information on testing algorithms for processing and reporting serological.
Outbreak Investigation: The First 48 Rachel Radcliffe, DVM, MPH Career Epidemiology Field Officer Division of Infectious Disease Epidemiology West Virginia.
Hepatitis web study H EPATITIS W EB S TUDY Hepatitis A: Epidemiology Presentation Prepared by: David Spach, MD and Nina Kim, MD Last Updated: May 31, 2011.
National Chlamydia Screening Programme Chlamydia testing and diagnoses in year olds, England January – December 2013 CTAD Team HIV & STI Department.
Hepatitis B: Epidemiology
Enhancing HIV/AIDS Surveillance in California California Department of Public Health Office of AIDS Guide for Health Care Providers.
Lyme’s Disease.
Lyme disease: Children and Outdoors School Activities Germaine Banza PUBH 6165 Walden University.
Unit 4 Part 2 Lyme Disease Terry Kotrla, MS, MT(ASCP)BB.
Babesiosis 1 st Quarter 2011 DIDE Training Jonah Long, MPH 1.
Tickborne Disease Epidemiology Fairfax County Fairfax County, VA, May 30, 2015 Shawn Kiernan District Epidemiologist Fairfax County Health Department.
Tickborne Disease Case Ascertainment Exercise First Quarter DIDE Training Zoonotic Disease Program.
Screening Introduction to Primary Care:
Sexually Transmitted Infections Mysheika Williams Roberts, MD, MPH Medical Director Assistant Health Commissioner Columbus.
National Program of Cancer Registries
 Martha’s Vineyard Boards of Health Tick-Borne Illness Initiative MDPH Internship 2012 Hannah Emily Nichols.
The Connecticut Experience with non-O157 STEC “Seek and Ye Shall Find” Sharon Hurd, MPH October 17, 2007 Connecticut Emerging Infections Program FoodNet.
Alliance Discussion with Office of AIDS: November HIV/AIDS Surveillance Surveillance overview HIV Incidence Surveillance Second Surveillance Stakeholder.
Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins Chapter 7 Epidemiology in Community Health Care.
Look-Alikes Tom Paige Department of Dermatology CCRMC.
HIV INCIDENCE SURVEILLANCE (HIS) PROGRAM California Department of Public Health Office of AIDS Surveillance Section.
Beyond Sputum Cups and Four Drugs The Responsibility of the Practicing Clinician in the Community Control of Tuberculosis V. R. Koppaka, MD, PhD Division.
CDC Guidelines for Use of QuantiFERON ® -TB Gold Test Philip LoBue, MD Centers for Disease Control and Prevention Division of Tuberculosis Elimination.
Links Between Testing and Reporting from the Laboratory Perspective Jyotsna Shah, Ph.D, CMLD, MBA February 25, 2004.
Public health impacts of donor screening for T. cruzi infection Susan P. Montgomery, DVM MPH Division of Parasitic Diseases Centers for Disease Control.
Severe Acute Respiratory Syndrome (SARS) and Preparedness for Biological Emergencies 27 April 2004 Jeffrey S. Duchin, M.D. Chief, Communicable Disease.
Public Health Perspective on SARS Diagnostics Stephen M. Ostroff Deputy Director National Center for Infectious Diseases, CDC.
Screening – a discussion in clinical preventive medicine Galit M Sacajiu MD MPH.
Epi Program Overview Disease Surveillance and Reporting.
Using Surveillance Indicators for Vaccine-Preventable Diseases: National Notifiable Diseases Surveillance System Sandra W. Roush, MT, MPH National.
Mumps Outbreaks Associated with Correctional Facilities Texas
PROS AND CONS OF LYME DISEASE TESTS:
Council of State and Territorial Epidemiologists
Understanding Epidemiology
Lyme’s Disease.
Infection Control Q and A APIC Greater NY Chapter 13 May 17, 2017 Beth Nivin BA MPH NYC DOHMH Communicable Disease Program
Lecture 11 serology Lyme’s Disease
CDC EIS Field Assignments Branch New Jersey Department of Health
California Clinical Laboratory Association
Continuing Medical Education Course Handout
Hepatitis Primary Care: Clinics in Office Practice
Introduction to public health surveillance
Varicella Vaccine Efficacy Estimates
National Immunization Conference
Presentation transcript:

Lyme Disease Epidemiology & Surveillance in Virginia David Trump, MD, MPH, MPA State Epidemiologist Director, Office of Epidemiology Virginia Department of Health

History of Lyme Disease Illness first described in Lyme, CT in 1975 By 1977, the Ixodes scapularis (black-legged) tick was linked with illness transmission In 1981, Borrelia burgdoferi was identified as the causative organism In 1984, CT initiated surveillance for Lyme disease In 1985, reported incidence of Lyme disease for all CT residents was 22/100,000 In 1989, Lyme disease became reportable by law in VA In 1991, Lyme disease became a nationally notifiable condition in the US

Lyme Disease in the United States Most commonly reported vector-borne illness in the US In 2011, 6 th most common nationally notifiable disease Does not occur nationwide Mostly concentrated in the Northeast and Upper Midwest

Reported Cases of Lyme Disease in USA

Reported Cases of Lyme Disease by State In 2011, Virginia ranked 10 th in the nation for number of annual cases reported to CDC That same year, Virginia ranked 14 th for incidence of Lyme disease Pennsylvania currently reports the most cases to CDC each year Delaware currently reports the greatest incidence each year * Incidence measured by confirmed and probable cases per 100,000 population

to 4.95 to to to to Cases per 100,000 population in Virginia, 2005 & 2011 Lyme Disease Incidence in Virginia, 2005 & 2012

Lyme Disease Incidence in Virginia,

Lyme Disease Incidence by Age Group, Virginia, 2012

Understanding Surveillance Data Surveillance case definitions establish uniform criteria for disease reporting Data on cases that meet the national surveillance case definition are shared with CDC Case definition should not be used as the sole criteria for clinical diagnosis Policies regarding case definitions, reporting, and data release are determined by states under the auspices of the Council of State and Territorial Epidemiologists (CSTE)

Surveillance Case Definition Confirmed A case of erythema migrans (EM) with a known exposure OR A case of EM with laboratory evidence of infection and without a known exposure OR A case with at least one late manifestation that has laboratory evidence of infection Probable Any other case of physician-diagnosed Lyme disease that has laboratory evidence of infection Suspected A case of EM where there is no known exposure and no laboratory evidence of infection OR A case with laboratory evidence of infection but no clinical information available (e.g., laboratory report only).

Surveillance Case Definition “Exposure” – Defined as having been (less than or equal to 30 days before onset of EM) in wooded, brushy, or grassy areas (i.e., potential tick habitats) in a county in which Lyme disease is endemic. A history of tick bite is not required. “Endemnicity” – A county in which Lyme disease is endemic is one in which at least two confirmed cases have been acquired in the county or in which established populations of a known tick vector are infected with B. burgdorferi.

Lyme Disease Endemic Localities in Virginia for 2013 Surveillance Franklin Brunswick New Kent Gloucester Galax Two or more Confirmed Cases (2005 – 2012)

Case Definition: “Laboratory Evidence of Infection” Positive Culture for B. burgdorferi, OR Two-tier testing - IFA/EIA positive or equivocal plus IgM Western Blot (WB) positive: Positive two tier test is sufficient only when blood was drawn ≤30 days from symptom onset, OR Single-tier IgG WB seropositive (interpreted by established criteria); sufficient at any point during illness, OR CSF antibody positive for B. burgdorferi by enzyme immunoassay (EIA) or immunofluorescence assay (IFA), when the titer is higher than it was in serum

Limitations of Surveillance Data Under-reporting and misclassification are features common to all surveillance systems. Not every case of Lyme disease is reported to CDC, and some cases that are reported may be due to another cause. Under-reporting is more likely to occur in highly endemic areas, whereas over-reporting is more likely to occur in non-endemic areas. Surveillance data is captured by county of residence, not county of exposure. Surveillance data are subject to each state's abilities to capture and classify cases. States may close their annual surveillance dataset at a different time than CDC. Thus, the final case counts published by CDC may not exactly match numbers published by each state agency for a given year.

Reporting Requirements By law, Lyme disease is a reportable condition in Virginia Report Lyme disease – when suspected or confirmed – to your local health department within three days

Reporting Requirements Lyme Disease is a reportable condition in Virginia: Code of Virginia and VAC and 12-VAC of the Board of Health Regulations for Disease Reporting and Control Local Health Department Directory:

§ Lyme disease testing information disclosure This new law places a requirement on practitioners who order tests for Lyme disease. As of July 1, 2013, “every licensee or his in-office designee who orders a laboratory test for the presence of Lyme disease shall provide to the patient or his legal representative” certain information.

§ Lyme disease testing information disclosure "ACCORDING TO THE CENTERS FOR DISEASE CONTROL AND PREVENTION, AS OF 2011 LYME DISEASE IS THE SIXTH FASTEST GROWING DISEASE IN THE UNITED STATES. YOUR HEALTH CARE PROVIDER HAS ORDERED A LABORATORY TEST FOR THE PRESENCE OF LYME DISEASE FOR YOU. CURRENT LABORATORY TESTING FOR LYME DISEASE CAN BE PROBLEMATIC AND STANDARD LABORATORY TESTS OFTEN RESULT IN FALSE NEGATIVE AND FALSE POSITIVE RESULTS, AND IF DONE TOO EARLY, YOU MAY NOT HAVE PRODUCED ENOUGH ANTIBODIES TO BE CONSIDERED POSITIVE BECAUSE YOUR IMMUNE RESPONSE REQUIRES TIME TO DEVELOP ANTIBODIES. IF YOU ARE TESTED FOR LYME DISEASE, AND THE RESULTS ARE NEGATIVE, THIS DOES NOT NECESSARILY MEAN YOU DO NOT HAVE LYME DISEASE. IF YOU CONTINUE TO EXPERIENCE SYMPTOMS, YOU SHOULD CONTACT YOUR HEALTH CARE PROVIDER AND INQUIRE ABOUT THE APPROPRIATENESS OF RETESTING OR ADDITIONAL TREATMENT."

Where can I find Lyme disease statistics? CDC Webpage: VDH Reportable Disease Surveillance Data e/SurveillanceData/ e/SurveillanceData/ Morbidity and Mortality Weekly Report (MMWR)

Role of Public Health: Prevention and Control VDH Contribute to the understanding of Lyme disease Education of public and providers Conduct surveillance for Lyme disease in Virginia Emphasis on prevention Primary prevention Secondary prevention CDC Maintaining and analyzing national surveillance data for Lyme disease Conducting epidemiologic studies Offering diagnostic and reference laboratory services Developing/testing strategies for the control and prevention Lyme disease in humans Supporting education of the public and health care providers

Thank You!